Lysosomal Trapping in CNS Drug Discovery | Alan Scientific

A small molecule crosses the blood–brain barrier and produces a high concentration in brain tissue.

At first glance, that looks like a successful CNS compound.

But for some molecules, particularly lipophilic weak bases, part of that apparent brain exposure may reflect accumulation inside acidic intracellular compartments such as lysosomes rather than freely available drug near the intended target.

This phenomenon is commonly referred to as lysosomal trapping or lysosomal sequestration.

The distinction matters because total brain concentration and pharmacologically useful target-site exposure are not always the same.

A 2026 study from Amgen developed a rapid screening and confirmation workflow for lysosomotropic compounds and showed that lipophilic brain-active basic molecules frequently exhibited lysosomal trapping. The authors also highlighted the potential consequences for unbound drug concentration, pharmacological response and phospholipid metabolism.

High brain accumulation does not necessarily mean high target-site exposure.

Why Weak Bases Become Trapped in Lysosomes

Lysosomes maintain a substantially more acidic internal environment than the surrounding cytosol.

A weakly basic compound may exist partly in an uncharged form at cytosolic pH. That neutral fraction can cross biological membranes relatively efficiently.

After entering the acidic lysosomal lumen, protonation increases. The more highly charged form crosses the lysosomal membrane less readily, so drug can progressively accumulate within the compartment.

Lipophilicity can reinforce this behavior by supporting membrane entry and membrane association.

The relevant medicinal-chemistry pattern is therefore not simply “basic compound.” The combination of basicity, lipophilicity and cellular permeability is much more informative.

Figure 1. Why weak bases become trapped in lysosomes. A membrane-permeable neutral fraction can enter the acidic lysosomal compartment, where protonation shifts the molecule toward a charged form with reduced membrane escape.

Brain Exposure Has More Than One Spatial Layer

BBB pharmacokinetics is often discussed in terms of plasma concentration, brain concentration and unbound brain exposure.

For intracellular CNS targets, another level becomes important.

After entering brain tissue, a compound can distribute between extracellular fluid, cytosol, cellular membranes, lysosomes, mitochondria, nuclei and other intracellular compartments.

Those compartments are not pharmacologically equivalent.

A molecule intended to inhibit a cytosolic enzyme must maintain sufficient available concentration near that target. If a large fraction of the compound becomes sequestered in lysosomes, total tissue exposure may look favorable while the relevant target-site concentration remains lower than expected.

This is consistent with the broader pharmacokinetic principle that total tissue concentration can differ substantially from unbound and pharmacologically relevant concentration because of tissue binding, partitioning and intracellular transport processes.

For many CNS programs, the lower rows of this table become increasingly important once basic BBB penetration has already been achieved.

When High Brain Concentration Can Be Misleading

Consider two compounds with similar total brain concentrations.

Compound A distributes relatively evenly through the relevant intracellular space and maintains useful free concentration near its target.

Compound B enters the same tissue but accumulates extensively inside lysosomes.

A whole-brain homogenate may make the two compounds appear similar.

Their pharmacology may not be.

Figure 2. Same total brain concentration does not guarantee the same target-site exposure. Lysosomal sequestration can contribute to measured brain accumulation while leaving less drug available around a non-lysosomal intracellular target.

This is one reason total brain exposure should not be interpreted in isolation.

Even strong BBB penetration does not reveal every intracellular concentration gradient that develops after the drug enters brain cells.

Experimental Evidence Supports pH-Dependent Intracellular Accumulation

A 2024 brain-slice study examined several marketed CNS-active weak bases and found intracellular accumulation within brain parenchymal cells.

The investigators then altered intracellular pH gradients using monensin and bafilomycin A1.

Monensin almost eliminated the observed intracellular accumulation for several compounds, bringing the intracellular-to-unbound concentration relationship close to unity. Bafilomycin produced a similar but smaller effect.

These results support an important role for pH partitioning and lysosomal trapping in the intra-brain distribution of the compounds studied.

This type of experiment is valuable because it distinguishes a mechanistic explanation from a purely structural prediction.

A compound may look lysosomotropic from its physicochemical properties, but changing the lysosomal pH gradient provides stronger evidence that intracellular accumulation is actually pH dependent.

The Chemistry That Helps Cellular Entry Can Create a Second Liability

Many CNS medicinal-chemistry programs deliberately optimize properties that support membrane permeability.

That is necessary.

But once sufficient permeability has been achieved, some of the same properties may begin to create a different problem.

Lipophilic weak bases can enter cells efficiently, yet their ionization behavior may favor accumulation inside acidic organelles.

The 2026 Amgen work reinforces this point. Basic ECCS class 2 compounds were consistently associated with lysosomotropic behavior, while permeability was an important part of whether those compounds could gain access to the intracellular compartment in the first place.

BBB optimization should not be treated as a one-directional attempt to maximize permeability.

Once permeability is adequate, intracellular distribution can become the next optimization problem.

Lysosomal Trapping Is Not Automatically a Negative Property

Lysosomal accumulation is not universally undesirable.

Its significance depends on the biology of the target.

For a cytosolic, nuclear or mitochondrial target, strong lysosomal sequestration may reduce useful drug availability.

For a drug whose biology directly involves lysosomes, enrichment in that compartment may instead be advantageous.

Lysosomal accumulation may also alter the duration of intracellular exposure by acting as a reservoir.

The better medicinal-chemistry question is therefore:

Does the subcellular distribution of the compound match the location and pharmacology of the intended target?

That framing is more useful than treating lysosomal trapping as automatically good or bad.

When Should a CNS Program Investigate Lysosomal Trapping?

No single descriptor proves that a compound will undergo biologically important lysosomal sequestration.

Suspicion becomes stronger when several observations occur together.

A compound series may contain basic molecules with substantial lipophilicity and good cellular permeability. Brain or cellular exposure may already look acceptable, yet target engagement or functional activity remains weaker than predicted from biochemical potency.

That type of PK/PD disconnect is a reasonable trigger for a more detailed intracellular-distribution analysis.

Figure 3. When lysosomal trapping becomes a plausible explanation. Basicity, lipophilicity and permeability become particularly relevant when adequate brain accumulation is accompanied by unexpectedly weak target engagement.

In such a situation, simply increasing total brain exposure may address the wrong problem.

The molecule may already be entering the brain successfully.

The more relevant question is where the molecule goes after cellular entry.

How Lysosomal Trapping Can Be Evaluated

Experimental approaches vary in throughput and mechanistic depth.

Fluorescence-based assays can provide relatively rapid screening for lysosomal accumulation. Direct analysis of lysosomal fractions can provide stronger quantitative evidence of compound enrichment. Perturbation of the lysosomal pH gradient can help determine whether the observed distribution is truly dependent on acidic intracellular compartments.

The 2026 Amgen study is useful because it combined rapid fluorescence-based screening with confirmatory approaches and emphasized that current methods still involve a trade-off between throughput and direct measurement.

The same paper also points to an important computational limitation: publicly available, broadly validated in-silico tools for lysosomotropism remain limited.

This matters when AI-generated ADMET outputs are interpreted.

Where AI Can Help

AI can still add value before a fully validated dedicated lysosomal-trapping model exists.

A useful computational workflow can identify physicochemical risk patterns across a chemical series, compare analogs and determine which structural changes appear to increase or reduce the likelihood of intracellular sequestration.

It can also help medicinal chemists understand whether basic pKa, lipophilicity, permeability or another molecular feature is driving the trend.

For current drug discovery, the defensible use of AI is therefore to identify risk, compare analogs, explain structural drivers and prioritize experimental confirmation.

Reporting an apparently precise lysosomal-trapping probability without adequate experimental data would be much harder to defend.

Alan Scientific View: BBB Optimization Should Not End at the BBB

For many CNS programs, the first objective is achieving sufficient unbound brain exposure.

For intracellular targets, that is increasingly only part of the problem.

A more complete interpretation considers systemic exposure, BBB transport, brain exposure, cellular entry, subcellular distribution and target engagement as related but distinct questions.

Not every CNS project requires a lysosomal-trapping assay.

The issue becomes especially relevant when a program shows a recognizable mismatch: brain exposure appears acceptable, but intracellular pharmacology does not.

In that situation, increasing lipophilicity or permeability again may not improve the compound.

The more useful medicinal-chemistry question may be:

Where is the drug actually accumulating inside the brain cell?

Conclusion

Lysosomal trapping adds an important subcellular layer to CNS drug-distribution analysis.

For lipophilic weak bases, high brain or cellular concentration can partly reflect sequestration inside acidic organelles rather than pharmacologically useful exposure near the intended target.

Experimental studies now provide increasingly direct evidence that pH-dependent intracellular accumulation can materially influence the distribution of brain-active small molecules.

The practical lesson is simple:

Do not interpret brain accumulation without considering intracellular location.

As CNS pharmacokinetics becomes more quantitative, BBB penetration and subcellular distribution should increasingly be evaluated as connected parts of the same exposure problem.

Related Technical Resources

BBB Permeability Prediction: Key Metrics and How to Interpret Them

ADMET & BBB Prediction

Selected References

Enogieru OJ, Nguyen M, Zou L, et al. Rapid screening approaches to identify and confirm lysosomotropic agents among ECCS class 2 basic drugs. Biochemical and Biophysical Research Communications. 2026;829:154185. DOI: 10.1016/j.bbrc.2026.154185.

Region-independent active CNS net uptake of marketed H+/OC antiporter system substrates. Frontiers in Cellular Neuroscience. 2024. The study investigated intracellular accumulation in brain slices and the effects of monensin and bafilomycin on pH-dependent distribution.

Smith DA, Rowland M. Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise. Drug Metabolism and Disposition. 2019;47(6):665–672. DOI: 10.1124/dmd.118.085951.